Effect of Leech Therapy and Herbal Ointment in Psoriasis

Phase 2

Not yet recruiting

• Conditions: Psoriasis, unspecified,

• Registration Number: CTRI/2021/07/034815
• Lead Sponsor: National Institute of Unani Medicine

Brief Summary

Psoriasis is achronic, inflammatory, hyperproliferative skin disease, characterized bywell-defined erythematous scaly plaques particularly affecting the extensorsurfaces and scalp. It usually follows a relapsing and remitting course.

Its management isunsatisfactory in conventional science. The drugs commonly employed forsystemic therapy are corticosteroids, Methotrexate, Retinoids and Cyclosporinsetc. Systemic medication carries a potential for more serious side effects thanthe topical therapy. Long term use of topical steroids causes dermal atrophy,tachyphylaxis and rarely adrenal suppression.

Unani Physiciansmentioned a wide range of treatment for Amraz-i-Jild includingTaqashshur-i-Jild and are treating the condition since a long time without muchserious side effects. The claims of Unani physicians should be validated onauthentic modern scientific parameters for worldwide acceptance. Keeping thesefacts in mind, this study is designed to evaluate the efficacy of Irsal-i-Alaq(Leech Therapy) and Zimad (Paste) in Taqashshur-i-Jild (Psoriasis).

Detailed Description

Not available

Study Timeline

• Study Start: 2021-07-15
• Last Update Posted: 2021-09-07

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Clinically diagnosed patients of Taqashshur-i-Jild 2.
• Willingness to participate in the study and follow the instructions.

Exclusion Criteria

• Uncontrolled Diabetes mellitus with RBS > 250 mg/dl 2.
• Hypotensive patient with BP <100/60mmHg 3.
• Bleeding disorders 4.
• Anaemia with Hb <10gm% 5.
• Acute infection and septicaemia 6.
• Immuno-compromised patients 8.
• Pregnant and lactating women 9.
• Other systemic disorders 10.Patients on blood thinking agents.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation for prognosis with averaged PASI	On 0 Day, 21st Day and 35th Day

Secondary Outcome Measures

Name	Time	Method
1. Dermatological Life Quality Index (DLQI)	2. Changes in the photographs of the affected site in fixed location and controlled illumination

Trial Locations

Locations (1)

National Institute of Unani Medicine; 🇮🇳 Bangalore, KARNATAKA, India

National Institute of Unani Medicine

🇮🇳Bangalore, KARNATAKA, India

Dr Mohd Nayab

Principal investigator

9019080556

nayabdr@gmail.com